{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:37:09Z","timestamp":1769315829302,"version":"3.49.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21DA057545"],"award-info":[{"award-number":["R21DA057545"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The presence of fentanyl in the drug supply is thought to contribute to the incidence of buprenorphine-precipitated opioid withdrawal (BPOW) during initiation. Long used as a surgical anesthetic and an analgesic, the utility of ketamine for psychiatric and substance use disorder indications continues to grow. We present a case of intravenous (IV) ketamine use on the general medical floor for the management of BPOW in a hospitalized patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 72-year-old male presented to the emergency room with new-onset hematuria and was admitted for urological intervention. Hematuria was successfully managed with continuous bladder irrigation over 3 days. Unfortunately, on hospital day two, the patient developed myalgias, restlessness, and later revealed ongoing non-medical use of illicit opioids. The addiction consultation service was consulted on the second day of hospitalization and made a new diagnosis of severe opioid use disorder. Two separate attempts at buprenorphine\/naloxone high-dose initiation to treat BPOW were not successful and the second was not responsive to standard symptomatic agents. An IV ketamine 27mg bolus was then administered, with an initial improvement followed by subsequent emergence delirium, which was addressed with IV haloperidol. The patient was eventually stabilized on buprenorphine\/naloxone 8mg twice daily prior to discharge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical significance<\/jats:title><jats:p>Ketamine may be an effective adjunctive agent in managing opioid withdrawal. Usually restricted to the intensive care unit and emergency department, this case report highlights both the potential and risks of IV ketamine on the general hospital floors. Further research is needed to better understand the safety of using ketamine to manage opioid withdrawal.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1586945","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:22:24Z","timestamp":1750396944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ketamine treatment for buprenorphine-precipitated opioid withdrawal: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ezioma","family":"Gbujie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Vercollone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"Everything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"B3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/adm.0000000000000929","article-title":"Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use","volume":"16","author":"Hailozian","year":"2021","journal-title":"J Addict Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/dar.13228","article-title":"Managing opioid withdrawal precipitated by buprenorphine with buprenorphine","volume":"40","author":"Oakley","year":"2021","journal-title":"Drug Alcohol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/add.16646","article-title":"Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review","volume":"120","author":"Gregory","year":"2024","journal-title":"Addiction"},{"key":"B6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A neuropharmacological model to explain buprenorphine induction challenges","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann Emergency Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001151","article-title":"Precipitated opioid withdrawal treated with ketamine in a hospitalized patient: A case report","volume":"17","author":"Christian","year":"2023","journal-title":"J Addict Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1876386301104010001","article-title":"Use of ketamine in ameliorating opioid withdrawal symptoms during an induction phase of buprenorphine","volume":"4","author":"Sota","year":"2011","journal-title":"Open Pain J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2022.08.183","article-title":"159 ketamine use for buprenorphine-precipitated opioid withdrawal: A case series of 10 patients","volume":"80","author":"Heeney","year":"2022","journal-title":"Ann Emergency Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaclp.2024.04.004","article-title":"Potential application of ketamine in pain and withdrawal in patients with opioid use disorder","volume":"65","author":"Casey","year":"2024","journal-title":"J Acad Consultation-Liaison Psychiatry"},{"key":"B11","unstructured":"UpToDate"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025411","article-title":"Opioid therapy for chronic pain","volume":"349","author":"Ballantyne","year":"2003","journal-title":"N Engl J Med"},{"key":"B13","article-title":"Effects of ketamine on precipitated opiate withdrawal","volume":"42","author":"Jovaisa","year":"2006","journal-title":"PubMed"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa074","article-title":"In-Hospital illicit drug use and patient-directed discharge: Barriers to care for patients with injection-related infections","volume":"7","author":"Eaton","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.06.011","article-title":"In-hospital illicit drug use, substance use disorders, and acceptance of residential treatment in a prospective pilot needs assessment of hospitalized adults with severe infections from injecting drugs","volume":"92","author":"Fanucchi","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31467-8","article-title":"Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial","volume":"390","author":"Avidan","year":"2017","journal-title":"Lancet"},{"key":"B17","article-title":"Haloperidol for the treatment of ketamine-induced emergence delirium","volume":"23","author":"Atlas","year":"2007","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jopan.2023.08.003","article-title":"Dexmedetomidine \u2013 an alternative to midazolam in the treatment of ketamine-induced emergence delirium: A systematic review","volume":"39","author":"Strickley","year":"2023","journal-title":"J PeriAnesthes Nurs"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1586945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:22:25Z","timestamp":1750396945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1586945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":18,"alternative-id":["10.3389\/fpsyt.2025.1586945"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1586945","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1586945"}}